Literature DB >> 9241712

Anemia, hypertension, and myocardial dysfunction in end-stage renal disease.

J Venkatesan1, W L Henrich.   

Abstract

Cardiovascular disease remains the major cause of mortality in patients with end stage renal disease (ESRD). The pathophysiology of cardiac dysfunction in ESRD is complex and not fully understood. However, it appears that the two major determinants of left ventricular (LV) hypertrophy and dysfunction are anemia and hypertension, both of which are very common in ESRD patients. Early and aggressive correction of anemia and hypertension may have a significant impact on cardiac disease in ESRD patients. This article presents a discussion on the management of anemia and hypertension, and the current information available on the pathogenesis and management of LV dysfunction in ESRD.

Entities:  

Mesh:

Year:  1997        PMID: 9241712

Source DB:  PubMed          Journal:  Semin Nephrol        ISSN: 0270-9295            Impact factor:   5.299


  3 in total

1.  The effectiveness of renal transplantation as a treatment for recurrent uremic cardiomyopathy.

Authors:  Colin B Josephson; Diego Delgado; J Schiff; Heather Ross
Journal:  Can J Cardiol       Date:  2008-04       Impact factor: 5.223

2.  Community outreach: a call for community action.

Authors:  Paul Crawford; Randall Maxey; Keith Dacosta
Journal:  J Natl Med Assoc       Date:  2002-08       Impact factor: 1.798

3.  Relation between mild to moderate chronic kidney disease and coronary artery disease determined with coronary CT angiography.

Authors:  Ivo A Joosen; Frank Schiphof; Mathijs O Versteylen; Eduard M Laufer; Mark H Winkens; Patricia J Nelemans; Jeroen P Kooman; Leonard Hofstra; Joachim E Wildberger; Tim Leiner
Journal:  PLoS One       Date:  2012-10-10       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.